Updated Phase 1 givastomig monotherapy data show an impressive 18% ORR in metastatic gastric cancer patients who had received ...

Arcturus stock drops on interim Phase 2 results for ARCT-032, showing promising mucus reduction in cystic fibrosis patients but no initial FEV₁ improvement.

Prime Minister Mark Carney said Wednesday during a pre-budget speech that Canada’s goal over the next decade is to “double ...

Terns Pharmaceuticals halts its TERN-601 obesity program due to insufficient efficacy and safety concerns. Click here to read ...

Middle-class shoppers flock to brands like The North Face and Dillard's as signs of their material comfort, and they aren't shy about it.

Arcturus Therapeutics shares plunged 56% after Phase 2 cystic fibrosis trial data showed no meaningful lung function ...

D oug Wilson has a white beard and a round belly, and is therefore somewhat Santa-like in appearance. He does not seem at all ...

Arcturus Therapeutics (ARCT) announced interim results from its ongoing Phase 2 clinical trial of ARCT-032, an investigational inhaled mRNA ...

Astral Resources says in-fill drilling at the Theia deposit of its Mandilla project in WA has continued to deliver broad ...

Merck KGaA could now have a head start in the race to market Precem-TcT, which could become the first widely approved ADC in ...

Study Acceptance Supports and Provides the Catalyst for Upcoming Commercial Rollout and Revenue-Generating PotentialUNIONDALE, NY, ...

Detailed price information for Atyr Pharma Inc (ATYR-Q) from The Globe and Mail including charting and trades.